Brief: Poolbeg Partners With Biopharma For Development Of Optimised Oral Drug To Treat Metabolic Condition
17/10/2023 07:40
Oct 17 (Reuters) - Poolbeg Pharma PLC POLB.L :
* POOLBEG PHARMA PLC - POOLBEG PARTNERS WITH A
NASDAQ-LISTED
BIOPHARMA
* POOLBEG PHARMA-STRATEGIC COLLABORATION AGREEMENT WITH
NASDAQ
LISTED BIOPHARMA CO FOR DEVELOPMENT OF OPTIMISED ORAL DRUG TO
TREAT METABOLIC CONDITION
Source text for Eikon: ID:nRSQ2985Qa
Further company coverage: POLB.L
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Poolbeg Pharma
See all newsBrief: Poolbeg Pharma Says European Patent Granted For POLB 001 In CRS
PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice